This Multicentre Study Compares aCUP-E With Standard Electrodes During aEEG Monitoring in NICU Newborns at Risk of Encephalopathy, Assessing Recording Quality, Reliability, Ease of Use and Safety. (aCUP HUSJR/J23)
Anàlisis Comparatiu Del Registre aEEG Realitzat Amb Elèctrodes Comercials i Amb l'Elèctrode aCUP-E (Advanced Cup Electrode) en Nounats Amb Risc de Patir Una Encefalopatia
This multicentre, observational, prospective and comparative study aims to validate the use of the new aCUP-E electrode for aEEG monitoring in newborns admitted to the NICU, comparing it with conventional electrodes currently used at two hospitals: Salut Sant Joan de Reus - Baix Camp and Hospital Universitari de Tarragona Joan XXIII.
A total of 35 newborns at risk of encephalopathy will be recruited.
During aEEG monitoring, one type of electrode will be placed on each cerebral hemisphere: on one hemisphere, the standard electrode normally used according to each hospital's protocol, and on the other, the new aCUP-E electrode. This design allows direct comparison under similar conditions to assess recording quality, reliability and ease of use. The multicentre methodology also facilitates a more representative and diverse sample, increasing the robustness and generalisability of the results.
This study seeks to determine whether aCUP-E can replace conventional electrodes, offering a safe and effective alternative that improves the quality of neonatal neurological monitoring and adapts to different clinical contexts.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Vicenç Pascual, Clinical Neurophisyiologist
- 電話番号：53160 34977 31 03 00
- メール：vicenc.pascual@salutsantjoan.cat
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Overall, the three cohorts together involve the inclusion of a maximum of 35 neonates, a number considered adequate to achieve the technical, functional and clinical objectives of the study, while maintaining a balance between methodological robustness, recruitment feasibility and minimisation of the care burden on an especially vulnerable population.
説明
Inclusion Criteria:
- Preterm or term newborns admitted to the NICU who are at risk of encephalopathy due to conditions arising from the clinical context. For example, maternal infection (e.g. maternal infections such as fever during labour, urinary tract infection, etc.), maternal history of gestational diabetes, gestational hypertension or preeclampsia, history of delivery complications such as placental displacement or abnormal placentation.
- Informed consent obtained from the parents or legal guardians of the newborns.
- Availability of aEEG monitoring equipment and aCUP-E electrodes during the study period.
Exclusion Criteria:
- Newborns with signs or symptoms of encephalopathy or any other evident neurological abnormality.
- Newborns with critical or unstable medical conditions that interfere with monitoring, such as the need for continuous mechanical ventilation or significant haemodynamic instability.
- Newborns receiving medication that may alter brain activity and interfere with aEEG results.
- Newborns with cranial or skin malformations that prevent proper electrode placement.
- Situations requiring urgent interventions that may interrupt monitoring or affect the quality of the data collected.
- Lack of informed consent from the parents or legal guardians of the newborns to participate in the study.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Cohort 1. Comparison between aCUP-E and liquid-gel electrodes
The first cohort will include 10 neonates, in whom an intra-individual comparison between aCUP-E and conventional liquid-gel electrodes will be performed. The main objective of this cohort is to externally validate the results obtained in the previous study authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS), file 918/21/EC-R, the results of which were subsequently published by Fabregat-Sanjuan et al. (Frontiers in Pediatrics, 2024). Therefore, the results obtained in these ten new patients will be compared with the results previously obtained in the initial study, with the aim of verifying the reproducibility of aCUP-E performance at a second hospital and confirming that its performance does not depend on the participating centre or the staff responsible for electrode placement. |
|
Cohort 2. Comparison between aCUP-E and needle electrodes
The second cohort will include 15 neonates, all recruited at Hospital Universitari de Tarragona Joan XXIII (HUJ23). In this cohort, a simultaneous comparison between aCUP-E and the needle electrodes routinely used in clinical practice will be performed. This is the first specific clinical evaluation between the two recording systems. In a paired intra-individual design, a cohort of approximately 10 neonates would allow an initial assessment of comparative performance to detect large intra-individual differences. |
|
Cohort 3. Monitoring exclusively using aCUP-E
The third cohort will include 10 neonates monitored exclusively using aCUP-E electrodes. This cohort is expected to be distributed evenly between the two participating centres, including approximately 5 neonates at Hospital Universitari de Tarragona Joan XXIII (HUJ23) and 5 neonates at Hospital Universitari Sant Joan de Reus (HUSJR), provided that the recruitment rate allows it. The main objective of this cohort is not to compare different types of electrodes, but to evaluate the technical feasibility, functional stability and safety of exclusive use of aCUP-E during complete monitoring sessions. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
1. To compare the overall recording quality of aCUP-E with that of commercial electrodes.
時間枠：Through study completion, an average of 2 years
|
This analysis will be performed in preterm and term newborns at risk of encephalopathy, selecting segments with low impedance and absence of artefacts to determine recording quality. The outcome will be a % of time of the recording with good quality |
Through study completion, an average of 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2. To evaluate the clinical feasibility of aCUP-E
時間枠：Through study completion, an average of 2 years
|
This outcome will evaluate the clinical feasibility in relation with standard practice. The outcome will be the results of a survey from clinicians. |
Through study completion, an average of 2 years
|
|
3. To evaluate the safety of aCUP-E
時間枠：Through study completion, an average of 2 years
|
This outcome will evaluate the safety of the electrode. The outcome will be the results of a survey from clinicians. |
Through study completion, an average of 2 years
|
|
4. To evaluate the reliability of aCUP-E recordings
時間枠：Through study completion, an average of 2 years
|
This outcome will evaluate the differences between recordings. The outcome will be the % of differences between recordings. |
Through study completion, an average of 2 years
|
|
5. To evaluate electrode survival and durability
時間枠：Through study completion, an average of 2 years
|
This outcome will evaluate the time to use in good conditions the electrode. The outcome will be the number of hours as a function of the % of survival. |
Through study completion, an average of 2 years
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。